These modified nanocarriers can be made to target certain immune cells, such as CD4+ T-cells, or elements of the cancer microenvironment, increasing the therapeutic index of checkpoint inhibitors, cytokines, and immunomodulators (Saeed et al., 2019). Here, CD4 is linked to cancer.